U.S. Infrastructure Stock News

NYSE:SITE
NYSE:SITETrade Distributors

SiteOne Landscape Supply (SITE) Stock Looks Cheap On Cash Flow While Earnings Look Pricey

SiteOne Landscape Supply stock has fallen 38.7% over the past five years, yet the current intrinsic value estimate using a Discounted Cash Flow (DCF) approach suggests the shares may still trade below that modelled value, while the broader valuation checks paint a less generous picture. Over five years, SiteOne Landscape Supply has declined 38.7%, which places extra focus on whether the current price reflects the company’s longer term cash flow potential. Future cash generation from its...
NYSE:DAL
NYSE:DALAirlines

Delta’s Higher Revenue but Lower Profit and Shelf Filing Could Be A Game Changer For Delta Air Lines (DAL)

In the second quarter of 2026, Delta Air Lines reported revenue of US$19,757 million, up from US$16,648 million a year earlier, while net income declined to US$1,604 million from US$2,130 million. Despite pressure from sharply higher fuel costs and lower earnings per share, Delta reaffirmed its full-year outlook and bolstered liquidity options by filing an omnibus shelf registration for multiple types of securities. Next, we’ll examine how Delta’s reaffirmed full-year outlook, despite record...
NasdaqGS:CEVA
NasdaqGS:CEVASemiconductor

Does Landmark AI Licensing Deal With Major Platform Player Change The Bull Case For CEVA (CEVA)?

Ceva, Inc. recently announced a landmark AI licensing agreement with a major U.S. software and AI platform company, centered on its NeuPro-M architecture for custom silicon in next-generation intelligent computing devices. This deal broadens Ceva’s reach beyond traditional chipmakers to influential software platform customers seeking tightly integrated hardware-software AI solutions at the edge. We’ll now examine how this push into custom AI silicon for software platform companies could...
NasdaqGM:AAOI
NasdaqGM:AAOICommunications

Can Applied Optoelectronics (AAOI) Still Look Fairly Valued After AI Demand?

Applied Optoelectronics stock has delivered a very large 5 year return, yet its current valuation picture is mixed, with the intrinsic value estimate from a Discounted Cash Flow (DCF) model pointing to a roughly fair price while other checks suggest the stock is not a clear bargain overall. Over the past 5 years, Applied Optoelectronics has returned about 15.9x, which puts extra focus on whether the current share price is still supported by its fundamentals. Investor expectations around...
NYSE:WRB
NYSE:WRBInsurance

W. R. Berkley (WRB) Names Carolina Casualty Chief As Valuation Stays In Focus

Why the latest leadership move at W. R. Berkley matters for shareholders W. R. Berkley (WRB) has appointed Paul J. Stock as president of Carolina Casualty, a move that puts an experienced transportation focused insurance executive in charge of a key operating unit. See our latest analysis for W. R. Berkley. Despite a 2.5% decline in the 1 day share price return to around $71.98, W. R. Berkley has seen its 30 day share price return of 5.4% and 90 day share price return of 8.9% align with a 1...
NasdaqGS:JAZZ
NasdaqGS:JAZZPharmaceuticals

Is Jazz Pharmaceuticals (JAZZ) Still Undervalued On Its Oncology And Neuroscience Growth Story?

Recent Performance Context for Jazz Pharmaceuticals Stock Jazz Pharmaceuticals (JAZZ) has drawn investor attention after a period of strong longer term returns, with the stock showing gains over the past year and past 3 years, alongside positive revenue and net income growth. See our latest analysis for Jazz Pharmaceuticals. At a share price of $238.05, Jazz Pharmaceuticals has had a 90 day share price return of 19.43% and a year to date share price return of 37.48%. The 1 year total...
NasdaqGM:ETON
NasdaqGM:ETONPharmaceuticals

Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build

Eton Pharmaceuticals (ETON) came into focus after Chief Business Officer David Krempa exercised 10,000 Restricted Stock Units, converting them into common shares as part of a multi-year equity grant. See our latest analysis for Eton Pharmaceuticals. The recent equity grant vesting comes at a time when Eton Pharmaceuticals’ share price has moved to $37.51, with a 30-day share price return of 18.74% and a year-to-date share price return of 130.69%, while the 1-year total shareholder return...
NYSE:GDDY
NYSE:GDDYIT

Should Questions Over GDDY’s Discount Disclosures Reshape Views On Its AI And SaaS Margin Story?

Kaplan Fox & Kilsheimer LLP has begun investigating GoDaddy Inc. for potential securities law violations tied to its past disclosure of fourth-quarter promotional pricing on dotcom domains and the resulting impact on reported revenue and bookings. This probe raises questions about how clearly GoDaddy communicated the effects of its discounting strategy, potentially adding a governance and transparency dimension to how investors assess the business. We’ll now examine how concerns over...
NasdaqCM:PLUG
NasdaqCM:PLUGElectrical

Plug Power (PLUG) Could Be 20% Undervalued As Hunter Valley Project Moves Ahead

Plug Power (PLUG) is back in focus after the Hunter Valley Hydrogen Hub in Australia reached a final investment decision, pushing a 50 MW green hydrogen project into execution and spotlighting the company’s GenEco electrolyzer deployments. See our latest analysis for Plug Power. Despite the Hunter Valley decision and liquidity moves such as the planned Graham, Texas project sale, Plug Power’s share price return has been choppy. A 1-year total shareholder return of 48.37% contrasts with steep...
NasdaqGS:RKLB
NasdaqGS:RKLBAerospace & Defense

Rocket Lab (RKLB) Completes VICTUS HAZE And Targets Iridium, Is It Still Undervalued?

Rocket Lab (RKLB) is back in the spotlight after completing the U.S. Space Force’s VICTUS HAZE mission ahead of tight timelines, while also moving to buy Iridium Communications in a US$8b all-stock deal. See our latest analysis for Rocket Lab. The latest VICTUS HAZE success and Iridium deal headlines come against a mixed backdrop for Rocket Lab’s stock, with a 1-day share price return of 2.71%, a 30-day share price return down 23.03%, a 1-year total shareholder return of 76.70%, and a 5-year...
NYSE:EPD
NYSE:EPDOil and Gas

Did EPD’s Modest Distribution Hike Just Reframe Enterprise Products Partners’ Income-Focused Investment Narrative?

Enterprise Products Partners L.P. recently declared a second-quarter 2026 cash distribution of US$0.56 per unit (US$2.24 annualized), a 2.8% increase over the prior-year quarter, payable on August 14, 2026 to unitholders of record on July 31, 2026. The announcement extends Enterprise Products Partners’ long-running pattern of distribution growth, reinforcing its appeal for income-focused investors who prioritize consistent cash payouts. We’ll now examine how this latest distribution increase...
NasdaqGS:LSCC
NasdaqGS:LSCCSemiconductor

Should Valuation Concerns And Insider Selling Require Action From Lattice Semiconductor (LSCC) Investors?

In the past few days, investors reassessed Lattice Semiconductor after research highlighted that the stock screens as very expensive relative to an estimated intrinsic value and flagged heavy insider share sales over the last quarter. This combination of valuation concerns and insider activity has sharpened market focus on whether expectations for the business have stretched beyond fundamentals. Next, we’ll examine how concerns about insider selling activity may influence Lattice...
NasdaqGS:CGON
NasdaqGS:CGONBiotechs

How CG Oncology’s Phase II Bladder Cancer Data and 2026 BLA Timeline Will Impact CGON Investors

CG Oncology recently reported positive early Phase II results for its lead bladder cancer therapy, cretostimogene grenadenorepvec, in combination with gemcitabine, and outlined plans to complete its biologics license application for high-risk BCG-unresponsive non-muscle invasive bladder cancer by the fourth quarter of 2026. This combination of encouraging clinical data and a clearer regulatory timeline has sharpened investor focus on the company’s potential role in treating a challenging...
NYSE:BCO
NYSE:BCOCommercial Services

Is Brink's (BCO) Still Below Fair Value After A 64% Return?

Brink's stock has delivered a strong 64.2% return over the past three years, yet the broader valuation checks paint a more mixed picture, which raises the question of how much upside is already reflected in the current US$109.12 share price. Over the last three years Brink's has returned 64.2%, which puts recent gains at the center of any discussion about whether the current price still offers value. Expectations around Brink's ability to sustain cash flow from its security and cash...
NYSE:ENR
NYSE:ENRHousehold Products

Energizer Holdings (ENR) Faces Growth And Debt Questions On A Cheap Looking Valuation

Fresh attention on Energizer Holdings (ENR) has been triggered by analysis pointing to two pressure points: softer organic revenue growth over the past two years and a balance sheet now viewed as highly leveraged. See our latest analysis for Energizer Holdings. The recent concerns around softer organic revenue and higher leverage come after a period where the share price has been relatively muted, with a 90-day share price return of 5.92% but a 3-year total shareholder return that declined...
NasdaqGS:BCRX
NasdaqGS:BCRXBiotechs

BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure

BioCryst Pharmaceuticals stock has rebounded in recent years but is still down about 40.0% over five years, which sits alongside valuation checks that currently lean cheap on traditional metrics. With recent news highlighting both a shift toward external innovation and takeover speculation, investors are trying to work out whether the recent strength in the share price is backed by the fundamentals or running ahead of them. The share price decline of about 40.0% over five years leaves long...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Is Krystal Biotech (KRYS) Too Expensive After A 440% Return?

Krystal Biotech’s stock has delivered a very large 439.7% return over the past five years, yet its current checks lean expensive, with a low value score and the market multiples suggesting investors are paying a premium for that track record. Over five years, shareholders have seen a 439.7% return, which puts extra focus on whether today’s price still reflects a reasonable entry point. Expectations for Krystal Biotech’s future revenue and cash flow can support a premium valuation, but any...
NasdaqGS:KTOS
NasdaqGS:KTOSAerospace & Defense

Drone Defense Stocks With Strong Balance Sheets In A Shaky Market

With inflation concerns, rising bond yields and geopolitical tensions pulling markets in different directions, many investors are looking for themes backed by solid balance sheets rather than short term momentum. That is where Financially Strong Drone Defense Stocks come in. This screener focuses on companies in the drone defense space that pair exposure to long term defense spending with healthier cash positions and lower reliance on expensive debt. In this article, you will see three stocks...
NYSE:UHAL
NYSE:UHALTransportation

How Investors May Respond To U-Haul Holding (UHAL) Authorizing a $350 Million Share Buyback

Earlier this week, U-Haul Holding Co’s board approved a US$350 million share repurchase program, supported by strong cash reserves and lower capital spending after major fleet and storage investments. The move, alongside recent quarterly cash dividends, underscores management’s confidence in U-Haul’s intrinsic value and its evolving approach to shareholder returns. Next, we’ll examine how this sizeable buyback authorization shapes U-Haul’s investment narrative, particularly around capital...
NasdaqGS:SKYW
NasdaqGS:SKYWAirlines

SkyWest (SKYW) Stock Still Looks Discounted On Earnings Despite Weaker Growth

SkyWest stock has delivered a strong 5 year return, yet after a recent analyst downgrade and a weaker 1 year share price performance, the valuation checks still lean toward the shares looking inexpensive rather than fully priced. SkyWest has returned 144.0% over the past 5 years, which puts the current debate squarely on whether the long run share price gains already reflect what the business can deliver. The appointment of Wade Steel as president and chief operating officer may support...
NYSE:CL
NYSE:CLHousehold Products

The Bull Case For Colgate-Palmolive (CL) Could Change Following Margin Strength But Slower Organic Growth

Recent analysis of Colgate-Palmolive highlighted that over the last two years it has delivered best-in-class unit economics, with an average gross margin of 60.4% and a free cash flow margin of 17.8%, underpinned by strong pricing power and differentiated products. At the same time, organic revenue growth of 3.6% year on year points to slower demand in Colgate-Palmolive’s core business, raising questions about how long its highly profitable model can maintain momentum without a stronger...
NasdaqCM:CLSK
NasdaqCM:CLSKSoftware

CleanSpark (CLSK) Signs 20 Year Lease With Tech Tenant Beyond Bitcoin Mining

CleanSpark (NasdaqCM:CLSK) signed a 20-year triple net infrastructure lease with a leading global technology company at its Sandersville, Georgia campus. The agreement focuses on high performance computing infrastructure and extends beyond CleanSpark’s core bitcoin mining activities. A letter of intent covers the company’s entire Texas power portfolio, pointing to expanded use of those assets under long-term contracts. CleanSpark has been best known as a bitcoin mining company, but this new...
NYSE:DG
NYSE:DGConsumer Retailing

Should Dollar General’s Rising Higher‑Income Shopper Mix Require Action From Dollar General (DG) Investors?

Earlier this year, Dollar General reported that more customers earning US$100,000 or more are shopping its stores, as economic pressures push higher-income households toward value options such as its strong US$1 price point and seasonal promotions like back-to-school. This shift suggests Dollar General is broadening its appeal beyond its traditional lower-income base, potentially reshaping the mix of where and how U.S. consumers seek everyday value. We’ll now explore how attracting more...
NYSE:RAMP
NYSE:RAMPSoftware

LiveRamp (RAMP) Stock Looks Cheap On Cash Flow But Fair On Earnings

LiveRamp Holdings has delivered a 38.4% gain year to date, yet its intrinsic value estimate from a Discounted Cash Flow (DCF) approach still points to the shares trading at a 43.0% discount. This raises the question of how much of that upside may already be reflected in the current US$37.94 price. The stock also scores well on broader valuation checks, so investors are weighing whether the proposed sale to Publicis Groupe fully reflects that assessment. Year to date, LiveRamp Holdings is up...